• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡托普利(SQ 14,225)对大鼠自发性高血压发展的预防作用

Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225).

作者信息

Ferrone R A, Antonaccio M J

出版信息

Eur J Pharmacol. 1979 Dec 7;60(2-3):131-7. doi: 10.1016/0014-2999(79)90211-5.

DOI:10.1016/0014-2999(79)90211-5
PMID:393524
Abstract

Indirect systolic blood pressure (SBP) was monitored in male, weanling, spontaneously hypertensive rats (SHR) maintained on water for 16 weeks (group A) or on captopril therapy (100 mg/kg/day in drinking water) for 4 (group B), 8 (group C), 12 (group D), 16 (group E) weeks. Weanling SHR of group A developed typical, time-related hypertension over a 16-week observation period. In marked contrast, SHR receiving captopril did not develop hypertension. Discontinuation of captopril after 4, 8, 12 or 16 weeks resulted in the usual development of hypertension. There was a transient increase in water consumption of drug treated rats which returned to normal by 8 weeks of dosing. Conversely, when captopril therapy was discontinued after 4, 8 or 12 weeks, there was a transient decrease in water intake, the magnitude of which was inversely related to the duration of drug therapy. These results demonstrate that daily captopril therapy was able to completely prevent the development of spontaneous hypertension. Explanations for the mechanism(s) underlying the influence of captopril on blood pressure and water intake remain speculative.

摘要

对雄性断乳自发性高血压大鼠(SHR)的间接收缩压(SBP)进行监测,这些大鼠分别在16周内只饮用普通水(A组),或接受卡托普利治疗(饮水中含100 mg/kg/天)4周(B组)、8周(C组)、12周(D组)、16周(E组)。在16周的观察期内,A组断乳SHR出现典型的、与时间相关的高血压。与之形成显著对比的是,接受卡托普利治疗的SHR未出现高血压。在4周、8周、12周或16周后停用卡托普利,会导致高血压的正常发展。接受药物治疗的大鼠饮水量有短暂增加,在给药8周后恢复正常。相反,在4周、8周或12周后停用卡托普利治疗时,饮水量会有短暂减少,其减少幅度与药物治疗持续时间呈负相关。这些结果表明,每日卡托普利治疗能够完全预防自发性高血压的发展。关于卡托普利影响血压和饮水量的潜在机制的解释仍属推测。

相似文献

1
Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225).卡托普利(SQ 14,225)对大鼠自发性高血压发展的预防作用
Eur J Pharmacol. 1979 Dec 7;60(2-3):131-7. doi: 10.1016/0014-2999(79)90211-5.
2
Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats.
Eur J Pharmacol. 1978 Oct 15;51(4):377-88. doi: 10.1016/0014-2999(78)90429-6.
3
The effects of chronic treatment with captopril in spontaneously hypertensive rats (SHR) and their offspring.卡托普利对自发性高血压大鼠(SHR)及其后代的长期治疗效果。
Clin Exp Hypertens A. 1984;6(6):1179-86. doi: 10.3109/10641968409039590.
4
Captopril and hypertension development in the SHR.卡托普利与自发性高血压大鼠的高血压发展
Clin Exp Hypertens (1978). 1980;2(6):1083-96. doi: 10.3109/10641968009037162.
5
The effects of captopril on blood pressure, urinary water and electrolyte excretion and drinking behaviour in Brattleboro rats.卡托普利对布拉特洛维大鼠血压、尿水和电解质排泄及饮水行为的影响。
Clin Sci (Lond). 1983 Dec;65(6):589-97. doi: 10.1042/cs0650589.
6
Chronic treatment with captopril, SQ29,852, hydralazine and a 33% fish meal diet in malignant stroke-prone spontaneously hypertensive rats.在恶性易中风自发性高血压大鼠中使用卡托普利、SQ29852、肼屈嗪和33%鱼粉饮食进行长期治疗。
J Hypertens. 1991 Dec;9(12):1105-17.
7
Blood pressure after captopril withdrawal from spontaneously hypertensive rats.
Hypertension. 1995 Jan;25(1):82-7. doi: 10.1161/01.hyp.25.1.82.
8
Failure of captopril to lower blood pressure in spontaneously hypertensive rats offered water and saline to drink.给自发性高血压大鼠提供水和盐水饮用时,卡托普利未能降低其血压。
Clin Exp Pharmacol Physiol. 1983 May-Jun;10(3):269-72. doi: 10.1111/j.1440-1681.1983.tb00195.x.
9
Prevention of the development of heart failure and the regression of cardiac hypertrophy by captopril in the spontaneously hypertensive rat.
Eur Heart J. 1983 Jan;4 Suppl A:143-8. doi: 10.1093/eurheartj/4.suppl_a.143.
10
Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1-7 and angiotensin II-induced perfusion pressure in isolated kidney in SHR.卡托普利可避免高血压、血浆血管紧张素II升高,但会增加自发性高血压大鼠离体肾脏中血管紧张素1-7及血管紧张素II诱导的灌注压。
Auton Autacoid Pharmacol. 2012 Oct;32(3 Pt 4):61-9. doi: 10.1111/aap.12001.

引用本文的文献

1
Oxidative Stress in Kidney Injury and Hypertension.肾脏损伤与高血压中的氧化应激
Antioxidants (Basel). 2024 Nov 27;13(12):1454. doi: 10.3390/antiox13121454.
2
Renal autoregulation in health and disease.健康与疾病状态下的肾自动调节
Physiol Rev. 2015 Apr;95(2):405-511. doi: 10.1152/physrev.00042.2012.
3
TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential.TDIQ(5,6,7,8-四氢-1,3-二氧杂环戊烯并[4,5-g]异喹啉):发现、药理作用及治疗潜力。
CNS Drug Rev. 2007 Winter;13(4):405-22. doi: 10.1111/j.1527-3458.2007.00022.x.
4
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.卡托普利:对其药理特性和治疗效果的初步综述。
Drugs. 1980 Dec;20(6):409-52. doi: 10.2165/00003495-198020060-00001.
5
Attenuation by SQ 14,255 (captopril) of the vascular response to noradrenaline in the rate isolated kidney.SQ 14,255(卡托普利)对离体肾血管对去甲肾上腺素反应的减弱作用。
Br J Clin Pharmacol. 1980 Dec;10(6):621-3. doi: 10.1111/j.1365-2125.1980.tb00521.x.
6
Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats.比较卡托普利和双肼屈嗪在自发性高血压大鼠高血压发展过程中的心肌和血管效应。
Br J Pharmacol. 1983 Nov;80(3):533-43. doi: 10.1111/j.1476-5381.1983.tb10726.x.
7
A physiological role for pressure-dependent renin release in long-term blood pressure control.压力依赖性肾素释放在长期血压控制中的生理作用。
Pflugers Arch. 1987 Nov;410(4-5):450-6. doi: 10.1007/BF00586524.
8
Preclinical studies on angiotensin converting enzyme inhibitors.血管紧张素转换酶抑制剂的临床前研究。
Cardiovasc Drugs Ther. 1987;1(1):15-27. doi: 10.1007/BF02125829.
9
Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.急性和慢性西拉普利治疗对自发性高血压大鼠的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):151S-158S. doi: 10.1111/j.1365-2125.1989.tb03476.x.